Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Increasing diversity in pediatric hematology/oncology.

Frugé E, Lakoski JM, Luban N, Lipton JM, Poplack DG, Hagey A, Felgenhauer J, Hilden J, Margolin J, Vaiselbuh SR, Sakamoto KM.

Pediatr Blood Cancer. 2011 Jul 15;57(1):147-52. doi: 10.1002/pbc.22977. Epub 2011 Jan 31.

2.

Quantitative trait loci (QTL) analysis of longevity in C57BL/6J by DBA/2J (BXD) recombinant inbred mice.

Lang DH, Gerhard GS, Griffith JW, Vogler GP, Vandenbergh DJ, Blizard DA, Stout JT, Lakoski JM, McClearn GE.

Aging Clin Exp Res. 2010 Feb;22(1):8-19.

PMID:
20305363
3.

Genetic architecture for hole-board behaviors across substantial time intervals in young, middle-aged and old mice.

Foreman JE, Lionikas A, Lang DH, Gyekis JP, Krishnan M, Sharkey NA, Gerhard GS, Grant MD, Vogler GP, Mack HA, Stout JT, Griffith JW, Lakoski JM, Hofer SM, McClearn GE, Vandenbergh DJ, Blizard DA.

Genes Brain Behav. 2009 Oct;8(7):714-27. doi: 10.1111/j.1601-183X.2009.00516.x. Epub 2009 Jun 23.

4.

Blood pressure and heart rate QTL in mice of the B6/D2 lineage: sex differences and environmental influences.

Blizard DA, Lionikas A, Vandenbergh DJ, Vasilopoulos T, Gerhard GS, Griffith JW, Klein LC, Stout JT, Mack HA, Lakoski JM, Larsson L, Spicer JM, Vogler GP, McClearn GE.

Physiol Genomics. 2009 Feb 2;36(3):158-66. doi: 10.1152/physiolgenomics.00035.2008. Epub 2008 Dec 9.

5.

Advancing institutional efforts to support research mentorship: a conceptual framework and self-assessment tool.

Keyser DJ, Lakoski JM, Lara-Cinisomo S, Schultz DJ, Williams VL, Zellers DF, Pincus HA.

Acad Med. 2008 Mar;83(3):217-25. doi: 10.1097/ACM.0b13e318163700a.

PMID:
18316865
6.

Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress.

Cavanaugh JE, Jaumotte JD, Lakoski JM, Zigmond MJ.

J Neurosci Res. 2006 Nov 1;84(6):1367-75.

PMID:
16941494
7.

Serum alkaline phosphatase activity is regulated by a chromosomal region containing the alkaline phosphatase 2 gene (Akp2) in C57BL/6J and DBA/2J mice.

Foreman JE, Blizard DA, Gerhard G, Mack HA, Lang DH, Van Nimwegen KL, Vogler GP, Stout JT, Shihabi ZK, Griffith JW, Lakoski JM, McClearn GE, Vandenbergh DJ.

Physiol Genomics. 2005 Nov 17;23(3):295-303. Epub 2005 Sep 13.

PMID:
16159911
8.

The Endocrine Society Ethics Advisory Committee: ethical aspects of conflicts of interests, October 2003.

Komesaroff PA, Bach MA, Danoff A, Grumbach MM, Kaplan S, Lakoski JM, Leitman D, Mellon S, Underwood LE, Leupen S; Endocrine Society Ethics Advisory Committee.

Endocrinology. 2004 Jun;145(6):3032-41. No abstract available.

PMID:
15140839
9.

Restricted feeding with scheduled sucrose access results in an upregulation of the rat dopamine transporter.

Bello NT, Sweigart KL, Lakoski JM, Norgren R, Hajnal A.

Am J Physiol Regul Integr Comp Physiol. 2003 May;284(5):R1260-8. Epub 2003 Jan 9.

10.

Duloxetine pharmacology: profile of a dual monoamine modulator.

Karpa KD, Cavanaugh JE, Lakoski JM.

CNS Drug Rev. 2002 Winter;8(4):361-76. Review.

11.

Functional mu opioid receptors are reduced in the spinal cord dorsal horn of diabetic rats.

Chen SR, Sweigart KL, Lakoski JM, Pan HL.

Anesthesiology. 2002 Dec;97(6):1602-8.

PMID:
12459691
12.

Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine.

Dugar A, Keck BJ, Maines LW, Miller S, Njai R, Lakoski JM.

Synapse. 2001 Feb;39(2):109-21.

PMID:
11180498
13.
14.

Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain.

Maines LW, Keck BJ, Smith JE, Lakoski JM.

Synapse. 1999 Apr;32(1):58-66.

PMID:
10188639
15.

Mentoring: who needs it?

Lakoski JM.

Curr Biol. 1999 Mar 11;9(5):R153. No abstract available.

16.

Expression of brain Gi protein in the aging F344 rat following exposure to corticosterone.

Maines LW, Polavarapu R, Lakoski JM.

Int J Dev Neurosci. 1998 Aug;16(5):341-6.

PMID:
9829170
18.

Age-dependent loss of corticosterone modulation of central serotonin 5-HT1A receptor binding sites.

Maines LW, Keck BJ, Dugar A, Lakoski JM.

J Neurosci Res. 1998 Jul 1;53(1):86-98.

PMID:
9670995
20.
22.
24.

Region-specific serotonin1A receptor turnover following irreversible blockade with EEDQ.

Keck BJ, Lakoski JM.

Neuroreport. 1996 Nov 4;7(15-17):2717-21.

PMID:
8981454
26.

Identification of central 5-HT and 5-HT1A receptors in the turtle brain (Chrysemys picta).

Larson-Prior LJ, Bushey RM, Maines LW, Lakoski JM.

Neurosci Lett. 1996 Jul 12;212(2):79-82.

PMID:
8832643
27.

Neuroendocrinology of aging at the cellular level: membranes to neural circuits.

Lakoski JM.

Neurobiol Aging. 1994 Jul-Aug;15(4):519-20. Review. No abstract available.

PMID:
7969733
28.
29.

Acute, but not repeated, cocaine administration decreases renin secretion in the conscious male rat.

Lakoski JM, Rittenhouse PA, Bonadonna AM, Van de Kar LD.

Neurosci Lett. 1991 Jun 24;127(2):181-4.

PMID:
1881629
31.

The interaction of cocaine with serotonin dorsal raphe neurons. Single-unit extracellular recording studies.

Cunningham KA, Lakoski JM.

Neuropsychopharmacology. 1990 Feb;3(1):41-50.

PMID:
2137698
32.

The ontogeny of [3H]5-hydroxytryptamine binding in the lamb: effects of in vivo thyroidectomy.

Richards GE, Lakoski JM, Black EW, Halpern RE, Ball K, Gluckman PD.

Int J Dev Neurosci. 1990;8(5):541-7.

PMID:
2281815
33.

Aging but not estrogen alters regional [3H]5-HT binding in the CNS of female Fischer 344 rats.

Halpern RE, Black EW, Lakoski JM.

Neurosci Lett. 1989 Jul 3;101(3):293-8.

PMID:
2771173
34.

Cocaine interaction with central monoaminergic systems: electrophysiological approaches.

Lakoski JM, Cunningham KA.

Trends Pharmacol Sci. 1988 May;9(5):177-80. Review. No abstract available.

PMID:
3073549
35.

Electrophysiological effects of cocaine and procaine on dorsal raphe serotonin neurons.

Cunningham KA, Lakoski JM.

Eur J Pharmacol. 1988 Apr 13;148(3):457-62.

PMID:
3384007
36.

The interaction of cocaine with central serotonergic neuronal systems: cellular electrophysiologic approaches.

Lakoski JM, Cunningham KA.

NIDA Res Monogr. 1988;88:78-91. Review. No abstract available.

PMID:
3145459
37.
38.

Histamine-induced depression of serotoninergic dorsal raphe neurons: antagonism by cimetidine, a reevaluation.

Lakoski JM, Gallager DW, Aghajanian GK.

Eur J Pharmacol. 1984 Aug 3;103(1-2):153-6.

PMID:
6148254
39.
41.

Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity.

Gallager DW, Lakoski JM, Gonsalves SF, Rauch SL.

Nature. 1984 Mar 1-7;308(5954):74-7.

PMID:
6322004
42.
43.

Interaction of histamine H2-receptor antagonists with GABA and benzodiazepine binding sites in the CNS.

Lakoski JM, Aghajanian GK, Gallager DW.

Eur J Pharmacol. 1983 Mar 25;88(2-3):241-5.

PMID:
6133770
44.

RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.

Arnerić SP, Long JP, Williams M, Goodale DB, Mott J, Lakoski JM, Gebhart GF.

J Pharmacol Exp Ther. 1983 Jan;224(1):161-70.

PMID:
6401334
45.
46.

Attenuation of morphine's depression of serum luteinizing hormone by lesions in the amygdala.

Lakoski JM, Gebhart GF.

Neuroendocrinology. 1981 Aug;33(2):105-11.

PMID:
7022252
47.

The effect of morphine on the content of serotonin, 5-hydroxyindole acetic acid and substance-P in the nuclei raphe magnus and reticularis gigantocellularis.

Lakoski JM, Mohrland JS, Gebhart GF.

Life Sci. 1980 Dec 22-29;27(25-26):2639-44. No abstract available.

PMID:
6163939
48.

Dopamine neurons: effect of lergotrile on unit activity and transmitter synthesis.

Walters JR, Lakoski JM, Baring MD, Eng N.

Eur J Pharmacol. 1979 Dec 7;60(2-3):199-210.

PMID:
43259
49.

Effect of muscimol on single unit activity of substantia nigra dopamine neurons.

Walters JR, Lakoski JM.

Eur J Pharmacol. 1978 Feb 15;47(4):469-71. No abstract available.

PMID:
564775

Supplemental Content

Loading ...
Support Center